Author:
Ruan Qiaoling,Zhang Shu,Ai Jingwen,Shao Lingyun,Zhang Wenhong
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Rheumatology
Reference41 articles.
1. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098–1104. doi: 10.1056/NEJMoa011110
2. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3(3):148–155. doi: 10.1016/S1473-3099(03)00545-0
3. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, Group B (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48(8):2122–2127. doi: 10.1002/art.11137
4. Wolfe F, Michaud K, Anderson J, Urbansky K (2004) Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 50(2):372–379. doi: 10.1002/art.20009
5. Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ (2014) Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford). doi: 10.1093/rheumatology/keu172
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献